Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | COMT | P21964 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | MPI | P34949 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482140 | 0.78 | SMN1; SMN2 (1.00) | SMN1; SMN2TSHRMEN1KMT2AGAA | |
| SCHEMBL11775647 | 0.69 | SMN1; SMN2 (0.47) | SMN1; SMN2TSHRMEN1KMT2AGAA | |
| SCHEMBL5963314 | 0.69 | HPGD (0.68) | SMN1; SMN2TSHRMEN1KMT2AGAA | |
| SCHEMBL10689850 | 0.68 | SMN1; SMN2 (0.55) | SMN1; SMN2TSHRMEN1KMT2AGAA | |
| SCHEMBL564993 | 0.68 | SMN1; SMN2 (0.46) | SMN1; SMN2TSHRMEN1KMT2AGAA | |
| SCHEMBL11000015 | 0.67 | KDM4E (0.45) | SMN1; SMN2TSHRMEN1KMT2AKDM4E | |
| SCHEMBL9299526 | 0.67 | SMN1; SMN2 (0.53) | SMN1; SMN2TSHRMEN1KMT2AGAA | |
| SCHEMBL3655311 | 0.66 | TSHR (0.48) | SMN1; SMN2TSHRMEN1KMT2AGAA | |
| SCHEMBL6412476 | 0.62 | SMN1; SMN2 (0.48) | SMN1; SMN2TSHRMEN1KMT2AGAA | |
| SCHEMBL3248315 | 0.62 | DYRK1A (0.43) | SMN1; SMN2KMT2AGAAGSK3BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581477-B1 | CYCLOALKENE DICARBOXYLIC ACID COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2009-12-02 | — | — | EP | disclosed |
| US-7071355-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4 SC AG (DE) | 2006-07-04 | — | — | US | disclosed |
| EP-1581477-A1 | CYCLOALKENE DICARBOXYLIC ACID COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-20040176458-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4 SC AG (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004056746-A1 | CYCLOALKENE DICARBOXYLIC ACID COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176458-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | MSR1, PPARG, PPARA | SMN1; SMN2 4583/4885TSHR 1037/4885COMT 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.